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Abstract 
Background: Temozolomide (TMZ) is a first-line drug for the treatment of glioblastoma. Long-term TMZ-treated 
tumour cells acquire TMZ resistance by profound reprogramming of the transcriptome, proteome, kinome, metabo-
lism, and demonstrate versatile and opposite changes in proliferation, invasion, in vivo growth, and drug cross-
resistance. We hypothesized that chromosomal instability (CIN) may be implicated in the generation of TMZ-driven 
molecular and phenotype diversity. CIN refers to the rate (cell-to-cell variability) with which whole chromosomes or 
portions of chromosomes are gained or lost.
Methods: The long-term TMZ-treated cell lines were established in vitro (U251TMZ1, U251TMZ2, T98GTMZ and 
C6TMZ) and in vivo (C6R2TMZ). A glioma model was achieved by the intracerebral stereotactic implantation of C6 
cells into the striatum region of rats. Genomic and phenotypic changes were analyzed by conventional cytogenetics, 
array CGH, trypan blue exclusion assay, soft agar colony formation assay, scratch wound healing assay, transwell inva-
sion assay, quantitative polymerase chain reaction, and Western blotting.
Results: Long-term TMZ treatment increased CIN-mediated genomic diversity in U251TMZ1, U251TMZ2 and 
T98GTMZ cells but reduced it in C6TMZ and C6R2TMZ cells. U251TMZ1 and U251TMZ2 cell lines, established in 
parallel with a similar treatment procedure with the only difference in the duration of treatment, underwent indi-
vidual phenotypic changes. U251TMZ1 had a reduced proliferation and invasion but increased migration, whereas 
U251TMZ2 had an enhanced proliferation and invasion but no changes in migration. U251TMZ1 and U251TMZ2 cells 
demonstrated individual patterns in expression/activation of signal transduction proteins (e.g., MDM2, p53, ERK, AKT, 
and ASK). C6TMZ and C6R2TMZ cells had lower proliferation, colony formation efficiency and migration, whereas 
T98GTMZ cells had increased colony formation efficiency without any changes in proliferation, migration, and inva-
sion. TMZ-treated lines demonstrated a differential response to a reduction in glucose concentration and an increased 
resistance to TMZ re-challenge but not temsirolimus (mTOR inhibitor) or U0126 (MEK1/2 inhibitor) treatment.
Conclusion: Long-term TMZ treatment selected resistant genotype-phenotype variants or generated novel versatile 
phenotypes by increasing CIN. An increase of resistance to TMZ re-challenge seems to be the only predictable trait 
intrinsic to all long-term TMZ-treated tumour cells. Changes in genomic diversity may be responsible for heterogene-
ous phenotypes of TMZ-treated cell lines.
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Background
Temozolomide (TMZ), an imidazotetrazine derivative of 
the alkylating agent dacarbazine, is a first-line drug for 
the treatment of patients with glioblastoma. However, 
the TMZ efficiency is quite modest, with median over-
all survival ranging 9.4–19.0  months for radiotherapy 
combined with TMZ versus 7.3–17.1 months for radio-
therapy alone [1]. TMZ is also used in the treatment of 
brain metastases, melanoma, lymphomas, refractory 
leukaemia, neuroendocrine tumours, pituitary tumours, 
Ewing’s sarcoma, primitive neuroectodermal tumours, 
lung cancer and other tumours [2]. Most tumour cells 
are intrinsically resistant or rapidly acquire resistance 
to TMZ at pharmacotherapeutic concentrations [3–6]. 
Long-term TMZ treatment of glioblastoma cells induced 
profound changes in heterochromatin organization 
and DNA methylation [7], transcriptome [8–12], pro-
teome [13, 14], kinome [15], and metabolome [8, 10], 
remodeling of the entire electron transport chain and 
activation of oxidative stress responses [16, 17]. These 
changes impacted morphology, proliferation, adhe-
sion, migration, invasion, and drug cross-resistance 
in a versatile manner [7, 8, 14, 18–23]. Such a com-
plex phenotype adaptation certainly indicates intricate 
cellular and molecular defense mechanisms against 
TMZ. Additionally, the versatile phenotype responses 
to long-term TMZ treatment (Table  1) may point to 
the TMZ-promoted genome changes, which affect the 
organization and functionality of the genetic network 
(gene content, RNA and protein expression and their 
interaction). In fact, an acquisition of chemotherapy 
resistance is generally accompanied by genome evolu-
tion and, conversely, chromosomal instability (CIN) cor-
relates with (multi)drug resistance [24–34].
CIN refers to the rate of gain or loss of whole chro-
mosomes and portions of chromosomes, whereby the 
rate is defined as cell-to-cell variability or variability 
between cellular populations [35]. The dynamic numeri-
cal and structural chromosomal aberrations (genome 
chaos) result in profound alterations in gene expression, 
reprogramming of metabolic and signaling pathways 
and the generation of biochemical/phenotype diver-
sification of cancer cells. Long-term drug-treated cells 
demonstrate transcriptomic and proteomic changes, 
and differ from parental cells at the molecular and cellu-
lar levels [26, 30]. Despite extensive studies, the role of 
CIN in the generation of TMZ-driven phenotype diver-
sity and TMZ-based therapeutic failure has been poorly 
addressed.
Here, we characterized the genome-phenotype evolu-
tion of long-term TMZ-treated glioblastoma cell lines. 
TMZ treatment influenced genomic stability and pheno-
type diversity in a cell type-dependent manner by select-
ing resistant genotype-phenotype variants or generating 
Table 1 Long-term TMZ treatment of tumour cells results in versatile phenotype responses
Cell line Morphology Proliferation/
viability
Cell cycle 
distribution
Migration/
invasion
Growth in  
vivo/soft agar
Concentration/ 
treatment period
Refs
A172 No change 100 μM/1 mo [62]
C6 No change ↓ ↓ ↓ in soft agar 100 μM/1 mo in vitro or 
50 mg/kg/10 injections 
in vivo
this 
study
D54 Changed ↓ ↑ G0/G1
↓ G2/M
↑ up to 0.5 mM/
5 or 10 mo
[14]
CSC ↓ ↓ in vivo [10]
HEK293  
derivatives
No change ↓ ↓ in soft agar up to 120 μM/
3 mo
[23]
HeLa  
derivatives
No change No change or ↑ ↑ in soft agar up to 120 μM/
3 mo
[23]
Hs683 ↓ ↓ ↓ in vivo up to 1 mM/
10 mo
[8]
LN-308, LNT-229, 
LN-18
No change ↓ No change up to EC50/6 mo [7]
T98G ↓ No change No change in vivo up to 1 mM [19]
T98G No change No change No change ↑ in soft agar 100 μM/1 mo this 
study
U87 Changed ↑ up to IC50 = 150 µM/3 weeks [18]
U251 ↑ G2/M [21]
U251 No change ↓ or ↑ ↓ or ↑ No change in soft 
agar
up to 100 μM/
5 or 10 weeks
this 
study
U373 ↑ ↑ ↑ in vivo up to 1 mM [19]
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novel versatile phenotypes by promoting CIN. Our data 
indicate that in addition to the reported TMZ-driven 
hypermutation phenotype [36–38], TMZ-instigated 
changes in genome stability and heterogeneity may con-
tribute to the versatile phenotypic responses of tumour 
cells.
Results
Temozolomide promotes polyploidization and diverse 
karyotype changes
To reveal the TMZ-promoted karyotypic and pheno-
typic changes, U251TMZ1, U251TMZ2, T98GTMZ, and 
C6TMZ cells were derived by repetitively exposing U251, 
T98G and C6 cells to TMZ (100  µM) in  vitro, whereas 
C6R1 and C6R2TMZ cells were established in  vivo 
[50 mg/kg, 10 intraperitoneal (i.p.) injections]. The vehi-
cle-treated U251 cells were predominantly hyperdiploid 
with the mean number of chromosomes 53 ± 9.2; 11 % 
of cells contained more than 60 chromosomes/cell and 
4.5 % of cells had more than 90 chromosomes/cell (cal-
culated from 200 metaphases). In contrast, U251TMZ1 
cells were mainly hypertetraploid with the mean num-
ber of chromosomes 100 ±  8.2 (90 %). The U251TMZ2 
cells consisted of two subpopulations: a predominant 
subpopulation with a hyperdiploid karyotype (53.9 ± 7.5; 
60 %) and a subpopulation with a hypertetraploid karyo-
type (108.2 ± 13.4; 27 %). A total portion of U251TMZ2 
cells with more than 60 chromosomes/cell increased up 
to 40 % (Fig. 1a, b).
It was reported [11] that TMZ-resistant lines derived 
from a hyperdiploid SNB19 cell line (which is itself a 
derivative of U251 cells [23]) had deviations from a 
parental modal chromosome number or ploidy change, 
however, no analysis of CIN was performed. To visual-
ize and compare CIN between cell lines, we used karyo-
graphs, 3-dimensional graphs, where x-axis designates 
the normal and aberrant chromosomes (clonal and 
non-clonal chromosome aberrations (CCAs/NCCAs), 
y-axis—the chromosome copy numbers, and z-axis—the 
numbers of metaphases arrayed for comparison to each 
other [33]. The karyographs show the degree of clonality 
and variability of chromosomes between individual cells 
of a cell line by comparing the copy numbers of intact 
and abnormal chromosomes of metaphases to each other. 
The karyotype differences between cell lines were dem-
onstrated by alignment and comparison of karyographs 
of vehicle- and TMZ-treated derivatives. Karyotype 
changes of U251TMZ1 cells were accompanied by a loss 
of 5 CCAs, an acquisition of 21 new CCAs and a higher 
total number, frequency and per cell variation of NCCAs. 
Karyotype changes of U251TMZ2 hyperdiploid subpop-
ulation were a loss of 5 and a gain of 8 new CCAs with 
an increase in the total number and per cell variation of 
NCCAs, whereas polyploid subpopulation was charac-
terized by a loss of 4 and an acquisition of 17 new CCAs 
with an increase in the total number and per cell vari-
ation of NCCAs (Fig.  1c, d; Additional file  1: Table S1). 
Many CCAs were distinct between U251TMZ1 and 
U251TMZ2 cells. Analysis of array comparative genome 
hybridization (aCGH) data revealed striking differences 
in copy number alterations (CNAs) between U251, 
U251TMZ1 and U251TMZ2 cells (Fig.  1e; Additional 
file 2: Table S2).
Both T98G and T98GTMZ cells had a near-penta-
ploid karyotype with the mean numbers of chromo-
somes 121.5 ± 8.7 and 120 ± 8.3, respectively. Karyotype 
changes of T98GTMZ cells were accompanied by a loss 
of 13 CCAs, an acquisition of 20 new CCAs and a higher 
total number, frequency and per cell variation of NCCAs 
(Fig.  2a, b; Additional file  3: Table S3). The most obvi-
ous differences of CNAs between T98GTMZ and T98G 
cells were a loss of 4p15.2-p14 and 10p15.3-p11.21 in 
T98GTMZ cells and a gain of 2q37.1-q37.3, 5q35.1-q35.3, 
6p22.1-p21.31, 17q25.1q25.3, and a loss of 18q11.2-q12.1 
in T98G cells (Fig. 2c; Additional file 4: Table S4).
A morphometric analysis of C6R1 and C6R2TMZ gli-
oma volume after 2 weeks of i.p. injection of DMSO or 
TMZ showed apparent differences in growth (≈75 ver-
sus ≈30  mm3) (Fig.  3a). C6TMZ, C6R1 and C6R2TMZ 
cells were near-diploid with the mean chromosome 
numbers 40–41 (±4.1–7.1) (Fig.  3b, c) and presented 
the selected subclones of karyotypically heterogeneous 
C6 cell line. Karyotype changes of C6TMZ cells and to a 
larger extent of C6R2TMZ cells were characterized by a 
reduction of a total number of CCAs and NCCAs. Inter-
estingly, C6R1 also demonstrated a reduction of a total 
number of CCAs and NCCAs, suggesting that in  vivo 
TMZ-treated cells underwent a two-stage selection: by 
the rat brain microenvironment and TMZ treatment 
(Fig.  3d, e; Additional file  5: Table S5). The major aber-
rations detected by aCGH and shared by C6 derivatives 
were a gain of 7p21.1-q31.1 and a loss of 16q12.1-q24.3. 
Additionally, C6TMZ but not C6R2TMZ cells demon-
strated a gain of 4p16.1-q26 (Fig.  3f; Additional file  6: 
Table S6). Using the DAVID bioinformatics resource 
[39], a list of 613 well-annotated genes in this region was 
retrieved (Additional file  7: Table S7a). We also manu-
ally curated a list of published proteins/miRNAs that 
were shown to contribute to TMZ resistance (Addi-
tional file 8: Table S8). Then we cross-checked both lists 
and revealed at least 15 hits (marked in Additional file 7: 
Table S7a). Cross-checking with a list of 1221 putative 
genes extracted from the NCBI Map Viewer for the chro-
mosomal region of interest produced several additional 
hits (marked in Additional file 7: Table S7B). Thus, TMZ 
treatment in vitro favoured selection of cells with a gain 
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of the chromosomal region enriched in genes conferring 
resistance to TMZ. Copy number gain of the 4p16.1-
q26 region in only in  vitro TMZ-treated C6 cells may 
potentially result from a different TMZ concentration 
as well as in vitro versus in vivo cytotoxic effects. Firstly, 
tumour TMZ Cmax varied at 20.6  ±  13.4  µM/L across 
Fig. 1 The TMZ-treated U251TMZ1 and U251TMZ2 have an increased CIN and ploidy. a Representative karyograms of U251 and U251TMZ1. The 
structurally abnormal chromosomes are marked. b Distribution of chromosomes across 200 metaphases of U251 and U251TMZ2 cell lines. The 
insert table shows a percentage of metaphases with numbers of chromosomes >60 or >90. c The karyotype differences between cell lines were 
demonstrated by alignment and comparison of karyographs of vehicle- and TMZ-treated derivatives. A list of all CCAs/NCCAs (in the same order 
as depicted on the x-axis of karyographs) and their copy number variation can be found in Additional file 1: Table S1. d A summary of karyotypic 
parameters of each cell line. e Chromosomal ideograms showing the areas of genetic gain/loss. Bars on the left (red colour) represent areas of copy 
number loss, whereas bars on the right (green colour) represent areas of copy number gain. Detailed description of copy number alterations (CNAs) 
can be found in Additional file 2: Table S2
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glioma bearing rats after 20  mg/kg intra-venous (i.v.) 
injections [40]. Hence TMZ tumour concentration fol-
lowing 50 mg/kg i.p. injections, a dose used in this study, 
should still be lower than that used in culture (100 µM). 
Secondly, we and others demonstrated the formation 
in  vivo of connexin 43-mediated gap junction channels 
between glioma cells and astroglia [41, 42]; this commu-
nication significantly reduces TMZ cytotoxicity [43].
Temozolomide promotes versatile phenotype changes
To elucidate how TMZ affected oncogenic characteris-
tics of cells, we first analyzed cell proliferation. Previous 
studies demonstrated that the proliferation of long-term 
TMZ-treated glioblastoma cells was increased, decreased 
or unchanged (Table  1). U251 cells proliferated faster 
than U251TMZ1 cells but slower than U251TMZ2 
cells. No difference in proliferation between T98G and 
T98GTMZ cells was observed. C6TMZ and C6R2TMZ 
cells proliferated slower than C6 and C6R1 cells, respec-
tively. Furthermore, C6R1 and C6R2TMZ cells prolif-
erated slower than C6 and C6TMZ cells, respectively 
(Fig. 4a), suggesting that the rat brain microenvironment 
might preferentially select for slower-dividing C6 cells. 
On the other hand, in vivo grown C6 derivatives, adapted 
for the different metabolic and growth-stimulating 
microenvironment within the brain, may undergo stress, 
when reintroduced to an in  vitro culture. Additionally, 
we cannot exclude an effect of DMSO as it induced cyto-
toxicity at certain concentrations in  vivo [44]. However, 
much lower DMSO concentration/volume (20 %/200 µl) 
was injected during this study than was previously 
reported in ([44] and refs therein).
Previous studies showed that TMZ or radiotherapy 
with TMZ treatment of glioblastoma cells was associ-
ated with a reduced glucose uptake [10, 22]. To test the 
sensitivity of cell growth to a glucose concentration 
reduction, proliferation was analyzed in low-glucose 
medium (1  g/L glucose) and compared to high-glucose 
medium (4.5 g/L glucose). Proliferation of U251cells did 
not change, was slightly increased for U251TMZ1 cells 
but reduced for U251TMZ2 cells. Furthermore, in con-
trast to high-glucose medium, no significant difference 
in proliferation was observed between U251, U251TMZ1 
and U251TMZ2 cells in low-glucose medium (Fig.  4b). 
Both T98G and T98GTMZ cells were highly sensitive 
to a reduction in glucose concentration, demonstrating 
Fig. 2 The TMZ-treated T98GTMZ have an increased CIN. a The karyotype differences between cell lines were demonstrated by alignment and 
comparison of karyographs of vehicle- and TMZ-treated derivatives. A list of all CCAs/NCCAs (in the same order as depicted on the x-axis of 
karyographs) and their copy number variation can be found in Additional file 3: Table S3. b A summary of karyotypic parameters of each cell line. c 
Chromosomal ideograms showing the areas of genetic gain/loss. Bars on the left (red colour) represent areas of copy number loss, whereas bars on 
the right (green colour) represent areas of copy number gain. Arrows depict the most obvious copy number alteration (CNA) differences between 
cell lines. Detailed description of copy number alterations (CNAs) can be found in Additional file 4: Table S4
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significantly inhibited, comparable growth. Prolifera-
tion of C6 cells was also reduced in low-glucose medium, 
whereas no change in proliferation was detected for 
C6TMZ, C6R1 and C6R2TMZ cells (Fig.  4b). Signifi-
cantly, C6TMZ and C6R1 cells proliferated faster than C6 
cells in low-glucose medium, whereas proliferation of C6 
and C6R2TMZ cells was comparable (Fig. 4b).
An analysis of colony formation efficiency showed no 
significant difference between U251 and U251TMZ1 or 
U251TMZ2 cells; however, U251TMZ2 cells formed 
more colonies than U251TMZ1 cells. T98GTMZ cells 
formed more colonies than T98G cells, whereas C6TMZ 
and C6R2TMZ cells formed a fewer number of colonies 
than C6 and C6R1 cells, respectively (Fig. 4c). This is in 
agreement with the previous studies where it was dem-
onstrated that colony formation efficiency or growth 
in  vivo of long-term TMZ-treated cells was increased, 
decreased or unchanged (Table 1).
Fig. 3 Characterization of the TMZ-treated C6TMZ, C6R2TMZ and the in vivo control C6R1 cell lines. a Brain magnetic resonance imaging (MRI) of 
the vehicle and TMZ-treated C6R1 and C6R2TMZ gliomas after 2 weeks of treatment. b Representative karyograms of C6 and C6TMZ. The structur-
ally abnormal chromosomes are marked. c Distribution of chromosomes across 200 metaphases for each designated cell line. d The karyotype 
differences between cell lines were demonstrated by alignment and comparison of karyographs of vehicle- and TMZ-treated derivatives. A list of all 
CCAs/NCCAs (in the same order as depicted on the x-axis of karyographs) and their copy number variation can be found in Additional file 5: Table 
S5. e A summary of karyotypic parameters of each cell line. f The chromosome ideograms show the areas of genetic gain/loss. Detailed description 
of copy number alterations (CNAs) can be found in Additional file 6: Table S6
Page 7 of 16Stepanenko et al. Cancer Cell Int  (2016) 16:36 
U251TMZ1 cells migrated faster than U251 cells but 
no difference in migration was observed between U251 
and U251TMZ2 cells (Fig.  5a). Furthermore, no dif-
ference in migration was detected between T98G and 
T98GTMZ cells, whereas C6TMZ and C6R2TMZ cells 
migrated slower than C6 and C6R1 cells, respectively. 
In contrast to a migration analysis, transwell invasion 
assay demonstrated a lower and higher invasion rate of 
U251TMZ1 and U251TMZ2 cells, respectively (Fig. 5b). 
Similar to a migration analysis, no difference in invasion 
Fig. 4 Long-term TMZ treatment promotes diverse changes in proliferation, sensitivity to a glucose concentration reduction and colony formation 
efficiency in soft agar. a Cell proliferation in high-glucose medium. Cells were seeded at a density of 5 × 104 (U251 and T98G derivatives) or 1 × 104 
(C6 derivatives) and grown in a high-glucose (4.5 g/L) DMEM with 10 % FBS. On the 7th day of seeding, cells viability was evaluated by trypan blue 
exclusion assay. b Cell proliferation in high- glucose medium versus low-glucose medium (1 g/L). c Representative photographs of plates with 
stained colonies (upper panel) and graphs comparing colony formation efficiency of the designated cell lines (lower panel). *P < 0.05; **P < 0.01; 
***P < 0.001; NS non significant
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Fig. 5 Long-term TMZ treatment promotes diverse changes in migration and invasion. a Representative photographs and quantitation of wound 
closure in scratch wound healing assay. b Representative photographs and quantitation of a number of invaded cells in a transwell invasion assay. 
*P < 0.05; **P < 0.01; ***P < 0.001; NS non significant
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rate was observed between T98G and T98GTMZ cells. 
Similar results were obtained in the previous studies 
where migration or invasion of long-term TMZ-treated 
cells was found to be increased, decreased or unaffected 
(Table 1).
Quantitative real time PCR (qRT-PCR) analysis of the 
expression of stem cell markers CD133, OCT4, SOX2 
and NANOG showed more than a twofold up-regulation 
of only CD133 in U251TMZ1 and U251TMZ2 cells, 
whereas more than a twofold down-regulation of CD133 
was observed in T98GTMZ cells, OCT4 in T98GTMZ 
cells, and SOX2 in U251TMZ1 cells (Additional file  9: 
Figure S1a).
The TMZ-treated cell lines had individual patterns in 
expression/activation of signal transduction proteins 
(Fig.  6). An analysis of epithelial-mesenchymal transi-
tion (EMT) markers showed increased expression of 
Vimentin, Slug and Claudin-1 in U251TMZ2 cells and 
Vimentin in U251TMZ1 cells. No significant changes in 
EMT markers expression were revealed between T98G 
and T98GTMZ cells. U251TMZ2 but not U251TMZ1 
cells had increased expression of MDM2. In contrast, 
U251TMZ1 but not U251TMZ2 cells had increased 
pAKT1, pERK1/2, and ASK1. T98GTMZ cells had 
increased pAKT1, pERK but not ASK1 and MDM2. Both 
U251TMZ1 and U251TMZ2 cells but not T98GTMZ 
cells had increased total and phosphorylated p53 levels. 
T98GTMZ cells but not U251TMZ1 or U251TMZ2 cells 
expressed MGMT. In addition, no MGMT expression 
in U251, U251TMZ1 or U251TMZ2 cells was detected 
by qRT-PCR (Additional file  9: Figure S1b). No PARP 
expression changes or cleavage was observed. If we 
extrapolate this low-scale Western blot analysis data on 
the whole (phospho)proteome, a striking difference and 
individuality of each TMZ-treated cell line in comparison 
to control cells would be revealed as it was demonstrated 
previously [13–15].
Finally, we analyzed whether the TMZ-treated cells 
changed sensitivity to TMZ re-challenge. U251TMZ1 
and U251TMZ2 cells were less responsive to 20  µM 
TMZ. T98GTMZ but not T98G cells grew slightly faster 
in the presence of 20  µM TMZ, whereas their growth 
was comparably inhibited by 100  µM TMZ. Prolif-
eration of C6 cells was significantly inhibited by 20 or 
100 µM TMZ, whereas the relative ratios of growth inhi-
bition after TMZ re-challenge of C6 derivatives were 
C6  >  C6R1  >  C6TMZ  ≈  C6R2TMZ (Fig.  7a). All cell 
lines were highly sensitive to 2 µM temsirolimus (TEM, 
mTOR kinase inhibitor) with no changes in the sensitiv-
ity after long-term TMZ treatment (Fig. 7b). 5 µM U0126 
(an extensively studied experimental MEK1/2 inhibitor 
[45]) inhibited proliferation of U251TMZ2 but not U251 
or U251TMZ1 cells. Proliferation of both T98G and 
T98GTMZ cells was insensitive to U0126. In contrast, 
C6 derivatives were highly sensitive to U0126 with no 
change in response after TMZ treatment (Fig. 7c).
Discussion
In this study we characterized genome-phenotype 
changes of long-term TMZ-treated glioblastoma cell 
lines and found that TMZ may either increase or reduce 
genomic diversity (CCA/NCCAs) and tumour cell 
aggressiveness. An increase of resistance to TMZ re-
challenge seems to be the only fundamental common 
Fig. 6 Long-term TMZ-treated cells have an individual pattern of 
expression/activation of the EMT markers and signal transduction 
pathway components. Proteins were evaluated by Western blot 
analysis with specific antibodies. AKT v-akt murine thymoma viral 
oncogene homolog 1, ASK1 mitogen-activated protein kinase kinase 
kinase 5, ERK mitogen-activated protein kinase, MGMT O-6-methyl-
guanine-DNA methyltransferase, MDM2 MDM2 proto-oncogene, E3 
ubiquitin protein ligase, PARP poly (ADP-ribose) polymerase 1, Snail 
snail family zinc finger 1, Slug snail family zinc finger 2
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and predictable trait intrinsic to all long-term TMZ-
treated cells; all other phenotype responses were versatile 
(Table 1). Our data indicate that changes in genome sta-
bility and diversity may be responsible for individual and 
heterogeneous phenotypes of long-term TMZ-treated 
cells. It is worth emphasizing that U251TMZ1 and 
U251TMZ2 cell lines, established by parallel selection 
of the same parental cell line with the same chemother-
apy agent under similar treatment conditions with the 
only difference in the duration of treatment (10 versus 
5 weeks), underwent individual genomic and phenotypic 
evolution. The development of a heterogeneous range 
of drug-resistant lines with individual genomic and/or 
phenotypic changes from the same cell line, treated with 
the same chemotherapy agent (e.g., cisplatin, puromycin) 
was reported previously [3, 31].
The therapy-driven glioblastoma genome evolution 
was scarcely reported previously. An analysis of primary 
cell cultures established from three surgery glioblas-
toma specimens of the same patient (primary specimen 
and two consecutive recurrences after lomustine and 
TMZ therapy) demonstrated a distinct subclonal archi-
tecture, abnormalities in karyotypic pattern, and rates 
of proliferation and migration [46]. Extending research 
on additional matched primary and recurrent glioblas-
tomas, authors revealed that therapy either increased 
Fig. 7 Long-term TMZ treatment increases the resistance to TMZ re-challenge but not to TEM or U0126 treatment. a–c Proliferation of a vehicle 
or TMZ (20 or 100 µM), TEM (2 µM) or U0126 (10 µM) treated cells was compared. U251, T98G (5 × 104 cells) and C6 (1 × 104 cells) derivatives were 
treated for 7 days with a single dose of TMZ, TEM, or U0126 or a vehicle (DMSO did not exceed 0.1 % by volume). Cells viability was evaluated by 
trypan blue exclusion assay. *P < 0.05; **P < 0.01; ***P < 0.001; NS non significant
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chromosomal aberrations in some cases that correlated 
with relatively short overall survival or reduced genome 
diversity in other cases and these patients showed a 
much longer overall survival [46]. Recent sequencing 
of primary and TMZ-treated recurrent gliomas showed 
the TMZ-driven amplification of mutation heterogene-
ity (hypermutation phenotype) in IDH1-mutant but not 
IDH1-wild-type astrocytic gliomas [36–38]. High levels 
of MGMT methylation and intrinsic or acquired muta-
tions in the key MMR genes and/or MGMT were associ-
ated with hypermutation phenotype [36]. However, these 
studies were primarily focused on alterations in DNA 
sequence rather than on CIN.
The resistance acquisition to TMZ was widely attrib-
uted to O6-methylguanine-DNA methyltransferase 
(MGMT). Despite a relatively low proportion of the 
TMZ-driven cytotoxic O6-methylguanine lesion for-
mation (5  %), the methylated promoter of MGMT was 
considered one of the most robust predictor of TMZ 
response with inverse correlation [47, 48]. However, this 
generally good correlation between MGMT methylation 
and TMZ treatment response was recently challenged. 
The TCGA Research Network reported that MGMT pro-
moter methylation could serve as a predictive biomarker 
only in the glioblastoma classical subtype but not in the 
other subtypes (mesenchymal, proneural or neural) [49]. 
Moreover, clonal analysis of glioblastoma samples dem-
onstrated inter-tumor variability in MGMT promoter 
methylation and MGMT protein expression levels, which 
were inconsistent with TMZ responses [6]. Similarly, no 
correlation between the TMZ sensitivity and MGMT 
promoter methylation, mRNA or protein expression was 
revealed for eleven diffuse large B cell lymphoma cell 
lines [4]. Here we found that long-term TMZ-treated 
cells reduced sensitivity to TMZ re-challenge without 
changing MGMT mRNA or protein expression levels. 
On the other hand, previous reports based on transcrip-
tome analysis elucidated that complex individual genetic 
networks rather than a specific common mechanism 
conferred a different TMZ sensitivity [4]. Furthermore, 
the TMZ-resistant variants of Hs683, U87, and LNZ308 
cell lines demonstrated individuality in global miRNA 
expression, and the integrative miRNA/mRNA network 
analysis revealed obvious differences in the genetic net-
work in comparison to control cells [12]. A measurement 
of global kinase activity of five TMZ resistant cell lines 
revealed no common kinase-driven pathway of TMZ 
resistance, and two TMZ resistant lines demonstrated 
extreme kinomic activity differences in comparison to 
control cells [15]. Altogether, adaptation of tumour cells 
to long-term TMZ cytotoxicity and genotoxicity is asso-
ciated with profound diverse changes in the transcrip-
tome, proteome, kinome and metabolome [8–15], the 
versatile phenotype responses (Table  1), involvement of 
many proteins/miRNAs (Additional file 8: Table S8) (see 
also the recent large synthetic lethal screens for “TMZ-
sensitizing genes”) [9, 50] and DNA repair pathways [51].
The cancer stem cell hypothesis postulates a significant 
role of glioblastoma cancer stem cells (GSC) in therapy 
resistance and tumour recurrence. However, a recent 
study showed that clones of GSC had distinct tumouri-
genic potential that was determined by their genetic 
diversity rather than expression levels of different GSC-
associated markers (CD133, CD15, A2B5 or CD44) [52]. 
Moreover, although TMZ treatment induced conversion 
of non-GSC into GSC both in vitro and in vivo [53], the 
majority of patient-matched GSC and non-GSC cul-
tures (25 tested) had a similar TMZ responsiveness and 
in some cases GSC were even more sensitive [54]. These 
studies highlight the primary importance of genetic het-
erogeneity in tumorigenic potential of CSC-associated 
populations, and furthermore point to dynamic plasticity 
of tumor cells under TMZ therapy and no superiority of 
GSC over bulk tumor population in TMZ resistance.
There are approximately twenty current clinical stud-
ies using mTOR inhibitors for the treatment of gliomas 
[55]. However, phase II studies with recurrent glioblas-
toma reported no efficacy of TEM in the combination 
with TMZ, sorafenib, bevacizumab, or erlotinib [55]. 
Although we used a clinically relevant TEM concentra-
tion [56], the discrepancy between cell culture responses 
(Fig.  7b) and patient responses is obvious. It is worth 
noting that TEM is also able to induce/promote CIN in 
tumor and normal cells [57]. A targeted therapy failure in 
patients with recurrent glioblastoma after radiotherapy 
with TMZ [58] highlights the necessity to lower the evo-
lutionary potential of a tumour and constrain its dynam-
ics by directing efforts at reducing tumour population 
diversity, at potentiating the immune system and homeo-
stasis of the individual.
In conclusion, our current data improve the knowledge 
on the TMZ-instigated genome evolution and highlight 
the primary importance of genetic instability in chemo-
therapy failure as the more different combinations of 
molecular mechanisms exist within a cancer cell popu-
lation, the more likely a population adapts to drug cyto-
toxicity/genotoxicity. TMZ treatment-associated changes 
of the genetic network (gene content, RNA and protein 
expression and their interaction), which are governed by 
changes of the genome context (number and structure 
of chromosomes and their nuclear topology) may offer 
an explanation for why the versatile and opposite phe-
notype responses of long-term TMZ treated tumor cells 
were observed in different studies (Table  1). Although 
our study is limited to the use of established glioblas-
toma cell lines, our results are consistent with a recent 
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report on evolution of low-grade gliomas to aggressive 
high-grade glioblastoma in 6 of 10 patient cases due to 
an increased mutation load upon TMZ therapy [38]. Our 
results and the latter study suggest that the therapeutic 
promotion of excessive genetic instability/heterogene-
ity is a double-edged sword: while the primary response 
in the form of increased overall survival will be positive, 
the price for moderate inhibition of tumour growth will 
be changes in the genomic landscape, tumour subclonal 
architecture, and, eventually, promotion of cancer evolu-
tion, which ultimately impacts the therapeutic manage-
ment of recurrence.
Methods
Cell cultures
Human U251 (Bank of Cell Lines from Human and Ani-
mal Tissues, R.E. Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology, Kyiv, Ukraine), 
T98G (ATCC) and rat C6 (Pirogov Russian State Medi-
cal University, Moscow, Russia) glioma cell lines were 
grown in DMEM (HyClone, Thermo Scientific, UK) sup-
plemented with 10 % fetal bovine serum (FBS, HyClone) 
and 100 µg/ml penicillin/100 u/ml streptomycin (Sigma, 
USA) in an environment of 95  % air/5  % CO2. U251, 
T98G, and C6 cell lines are isocitrate dehydrogenase 1 
(IDH1)-wild-type. U251 is MGMT-negative; T98G is 
MGMT-positive.
Pharmacological agents
Temozolomide (TMZ, Sigma), Temsirolimus (TEM, 
Abcam Biochemicals, USA) and U0126 (Abcam Bio-
chemicals) were dissolved in DMSO to a concentration 
of 100 mM. The final DMSO concentration in the culture 
medium did not exceed 0.4 %. Stock solutions of all drugs 
were stored at −20 °C.
TMZ treatment of glioblastoma cells in vitro
U251, T98G, and C6 glioblastoma cell lines were treated 
with DMSO or TMZ (Sigma) twice with 25  μM, twice 
with 50 μM and then with 100 μM TMZ twice per week 
during 5  weeks (U251TMZ2, T98GTMZ and C6TMZ) 
or 10 weeks (U251TMZ1), followed by several weeks of 
washout (in the TMZ-free medium) before in vitro tests. 
DMSO did not exceed 0.1 % of the culture medium.
TMZ treatment of C6 cells in vivo
The animals were kept in accordance with the Guide-
lines on Laboratory Practices adopted by the Minis-
try of Health of the Russian Federation (Order 267, 19 
June 2003). The protocol stipulating animal treatment 
was approved by the Ethics Committee of N. I. Pirogov 
Russian State Medical University, and all rules and regu-
lations were followed during experimentation on animals. 
Glioma modeling was performed by the intracerebral ste-
reotactic implantation (Leica stereotactic device, USA) of 
C6 cells (5 × 105) into the striatum region of ketamine-
anesthetized adult female Wistar rats as described pre-
viously [59]. Rats with C6 glioma received 20  % DMSO 
(n  =  1, C6R1) or TMZ (n  =  1, C6R2TMZ) injected 
intraperitoneally (i.p.) three times per week at a dose of 
50 mg/kg. Rats were sacrificed after 10 injections. Glio-
mas were aseptically harvested, mechanically disaggre-
gated, and a cell suspension was seeded into adherent 
dishes. Cells were used at the passages 3–10 for analysis.
Conventional cytogenetics
Chromosome samples were prepared as described pre-
viously [23]. 200 metaphase plates were calculated for 
distribution of chromosome across cells. 20 metaphases 
(U251 and T98G derivatives) or 10 metaphases (C6 
derivatives) were described for chromosome abnormali-
ties, according to the International System for Human 
Cytogenetic Nomenclature (ISCN 2013). Clonal chro-
mosome aberrations (CCAs) were defined as aberrations 
found at least in two cells among examined metaphases, 
whereas non-CCAs (NCCAs) as aberrations detected in 
only one cell. The frequency of NCCAs in a cell line was 
calculated by dividing the number of metaphases display-
ing NCCAs to the total number of examined metaphases 
(×100 %). Only structural NCCAs were considered.
Array comparative genome hybridization (aCGH)
A total DNA was isolated using NucleoSpin Blood DNA 
extraction kit (Macherey–Nagel, Germany) according to 
the manufacturer’s instructions. To analyze copy num-
ber alterations (CNAs), aCGH was performed as detailed 
previously [23]. Human and rat cell lines were analyzed 
on the CytoSure Aneuploidy Array 15  k (Oxford Gene 
Technologies, UK) and 180 K microarrays (Agilent Tech-
nologies, USA), respectively. Image analysis of human 
and rat samples was carried out with CytoSure Analy-
sis Software (Oxford Gene Technologies) and Agilent 
CytoGenomics Edition 2.9.2.4, respectively.
Cell proliferation in a high and low‑glucose medium
Cells were seeded onto 6 cm dishes at a density of 5 × 104 
(U251 and T98G derivatives) or 1  ×  104 (C6 deriva-
tives) and grown in high-glucose (4.5 g/L) or low-glucose 
(1 g/L) DMEM with 10 % FBS. On the 7th day of seed-
ing, cells were harvested, incubated with trypan blue, 
and calculated using hemocytometer. Experiments were 
repeated at least three times.
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Cell viability test
U251, T98G (5 × 104 cells) and C6 (1 × 104 cells) deriva-
tives were seeded onto 6 cm dishes and incubated over-
night. The cells were treated for 7 days with a single dose 
of TMZ (20 and 100  µM), TEM (2  µM), U0126 (5  µM) 
or DMSO. Experiments were repeated at least three 
times. Cell viability was evaluated by trypan blue exclu-
sion assay instead of metabolically-based MTT or ATP 
assays, which are prone to over/underestimate cell viabil-
ity under cytotoxic stress [45].
Soft agar colony formation assay
5 × 103 cells were placed in 1.5 ml of 0.35 % low gelling 
temperature agarose (Gibco, Life Technologies, USA) 
with DMEM supplemented with 10  % FBS. 0.35  % top 
agarose was poured on 1.5 ml of solidified 0.5 % base aga-
rose/10  % FBS/DMEM. Cells were seeded in triplicates 
in a 35-mm dish and grown at 37 °C for 21 days to allow 
colony formation. Colonies were visualized by staining 
with 0.005 % crystal violet, photographed, counted using 
OpenCFU software [60], and expressed as the means of 
triplicates of four independent experiments.
Scratch wound healing assay
Using a P200 pipette tip, the scratches were made by 
scraping across the confluent cell monolayer. Pictures 
were taken at 0 and 16 h (C6 derivatives) or 24 h (U251 
and T98G derivatives) and automated image analysis was 
carried out using TScratch software [61] to avoid any 
potential bias in quantifying an extent of migration. At 
least twelve wound healing areas for each cell line were 
photographed and analyzed to take into account the dif-
ferences in cell density and widths of scratches. The per 
cent of wound area closure was calculated taking open 
wound area at 0 h for 100 %.
Cell invasion assay
A 24-well tissue culture plate-based Chemicon cell inva-
sion assay (QCM ECMatrix 550, Millipore, USA) was per-
formed according to the manufacturer’s protocol. 2 × 105 
cells were seeded to the inserts. After 24  h, five fields of 
invaded cells in each well were randomly photographed 
and counted manually. Test was performed two times.
Real time quantitative PCR
Total RNA was extracted from cell lines using TRI Rea-
gent (Sigma, #T9424) according to the manufacturer’s 
recommendations. Equal amounts of total RNA (5 μg for 
20 μl reaction mixture) were transcribed into cDNA with 
random hexamer primers and RevertAid Reverse Tran-
scriptase (Thermo Scientific, #EP0441). Twofold diluted 
cDNA and gene specific primers were mixed with Max-
ima SYBR Green qPCR Master Mix (2X) (Fermentas, 
#K0251) according to the manufacturer’s recommenda-
tions. qRT-PCR was run in triplicates on CFX96 RT-PCR 
Detection System (Bio-Rad). The amplification procedure 
of target genes was as follows: initial denaturing step at 
95 °C for 10 min, followed by 40 cycles of denaturation at 
95 °C for 15 s, annealing at 59 °C for 30 s and extension at 
72  °C for 30 s. Melting curve analysis was performed to 
confirm amplification specificity. To calculate the relative 
gene expression ratios (fold-change), CT method (also 
known as the 2−ΔΔCT method, expressed as ratios relative 
to control values after normalization to the internal con-
trol TBP—TATA-binding protein) was applied. CT values 
were derived using Bio-Rad CFX Manager 3.1.
Primers
TBP Forward: TGCACAGGAGCCAAGAGTGAA; 
Reverse: CACATCACAGCTCCCCACCA; CD133 For-
ward: CGTGGATGCAGAACTTGACAACGT; Reverse: 
ATACCTGCTACGACAGTCGTGGT; SOX2 Forward: 
GCCGAGTGGAAACTTTTGTCGGA; Reverse: CGT-
GTACTTATCCTTCTTCATGAGCGTC; OCT4 For-
ward: GGAGAAGGAGAAGCTGGAGCA; Reverse: GG 
CAGATGGTCGTTTGGCTGAATA; NANOG Forward: 
GTCTGGACACTGGCTGAATCCT; Reverse: CTCGCT 
GATTAGGCTCCAACCAT; MGMT Forward: CCTGG 
CTGAATGCCTATTTCCACCA; Reverse: GGATGAGG 
ATGGGGACAGGATTGC.
Western blot analysis
Total cell lysates were analyzed as described earlier [23]. 
The following antibodies were used: mouse anti-MGMT 
(Novus Biologicals; #NB100-168), rabbit anti-PTCH2 
(Cell Signaling; #2464), rabbit anti-ASK1 (Cell Signal-
ing; #8662), rabbit anti-MDM2 (Thermo Fisher Scien-
tific Pierce; #PA5-11353), rabbit anti-p53 (Millipore; 
#04-1083), rabbit anti-phospho-p53 (Ser6) (Millipore; 
#04-540), rabbit anti-PARP (Cell Signaling; #9542), rab-
bit anti-ERK1/2 (Millipore; #06-182), rabbit anti-phos-
pho-ERK1/2 (Thermo Scientific Pierce; #MA5-1574), 
rabbit anti-AKT1 (Millipore; #07-416), mouse anti-phos-
pho-AKT1 (Santa Cruz; sc-52940), mouse anti-β-actin 
(Sigma-Aldrich; A1978), the Epithelial-Mesenchymal 
Transition antibody sampler kit (Cell Signaling; #9782), 
anti- rabbit (Cell Signaling, #7074) and anti-mouse (Cell 
Signaling, #44209).
Statistical analyses
A two-sided t test was used to calculate the significance 
values (Statistica 10 Software, USA). Data showing p val-
ues of *P < 0.05, **P < 0.01, and ***P < 0.001 were con-
sidered significant. All experimental data are reported 
as mean and the error bars represent the experimental 
standard error (±standard deviation, SD).
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